JP Morgan Chase’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

JP Morgan Chase’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-49	Closed	–	–	7192
2022 Q1	$0	Buy	+49	New	+$141	﹤0.01%	7270
2021 Q4	–	Sell	-185	Closed	-$1K	–	7210
2021 Q3	$1K	Sell	185 -4,972	-96%	-$25.6K	﹤0.01%	6434
2021 Q2	$31K	Sell	5,157 -19,960	-79%	-$141K	﹤0.01%	5857
2021 Q1	$305K	Buy	25,117 +12,025	+92%	+$171K	﹤0.01%	4964
2020 Q4	$191K	Buy	13,092 +11,210	+596%	+$143K	﹤0.01%	4824
2020 Q3	$20K	Buy	+1,882	New	+$24.1K	﹤0.01%	5151

JP Morgan Chase's CMPI Position: Q2 2022 in Review

JP Morgan Chase sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 49 shares.

JP Morgan Chase first reported a position in CMPI in Q3 2020 and held it in 6 quarters. The position peaked at $305K in Q1 2021. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

JP Morgan Chase reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
JP Morgan Chase sold 49 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022.
JP Morgan Chase first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 6 quarters.
JP Morgan Chase's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $305K in Q1 2021.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.